Serum surfactant protein D is correlated to development of dementia and augmented mortality

Clinical Immunology

Volumn 123, Issue 3, 2007, Pages 333-337

  Nybo, Mads ^a   Andersen, Kjeld ^b   Sorensen, Grith L ^b   Lolk, Anette ^b   Kragh Sorensen, Per ^a   Holmskov, Uffe ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Alzheimer's disease; Cholesterol; Dementia; Inflammation; Mortality; Surfactant protein D

Indexed keywords

SURFACTANT PROTEIN D;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; FEMALE; FOLLOW UP; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INFLAMMATION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; C-REACTIVE PROTEIN; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; RISK FACTORS; SEX FACTORS; SMOKING; SPECTROPHOTOMETRY; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 34249317212     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.03.001     Document Type: Article

References (29)

1. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 12 (2006) 1005-1015
2. Abraham C.R. Reactive astrocytes and alpha-1-antichymotrypsin in Alzheimer's disease. Neurobiol. Aging 22 (2001) 931-936
3. Dufouil C., Richard F., Fievet N., et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 64 (2005) 1531-1538
4. Pappolla M.A., Bryant-Thomas T.K., Herbert D., et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61 (2003) 199-205
5. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
6. Grimm M.O., Grimm H.S., Patzold A.J., et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 7 (2005) 1118-1123
7. Holmskov U., Thiel S., and Jensenius J.C. Collections and ficolins: humoral lectins of the innate immune defense. Annu. Rev. Immunol. 21 (2003) 547-578
8. Ofek I., Mesika A., Kalina M., et al. Surfactant protein D enhances phagocytosis and killing of unencapsulated phase variants of Klebsiella pneumoniae. Infect. Immun. 69 (2001) 24-33
9. Madsen J., Kliem A., Tornoe I., Skjodt K., Koch C., and Holmskov U. Localization of lung surfactant protein D on mucosal surfaces in human tissues. J. Immunol. 164 (2000) 5866-5870
10. Leth-Larsen R., Nordenbaek C., Tornoe I., et al. Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia. Clin. Immunol. 108 (2003) 29-37
11. Sorensen G.L., Madsen J., Kejling K., et al. Surfactant protein D is proatherogenic in mice. Am. J. Physiol.: Heart Circ. Physiol. 290 (2006) H2286-H2294
12. Clark H., and Reid K. The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema. Arch. Dis. Child. 88 (2003) 981-984
13. Botas C., Poulain F., Akiyama J., et al. Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 11869-11874
14. Sorensen G.L., Hjelmborg J.V., Leth-Larsen R., et al. Surfactant protein D of the innate immune defense is inversely associated with human obesity and SP-D deficiency infers increased body-weight in mice. Scand. J. Immunol. 64 (2006) 633-638
15. Andersen K., Lolk A., Nielsen H., Olsen J., and Kragh-Sorensen P. Prevalence of very mild to severe dementia in Denmark. Acta Neurol. Scand. 96 (1997) 82-87
16. Lolk A., Nielsen H., Andersen K., Andersen J., and Kragh-Sorensen P. CAMCOG as a screening instrument for dementia: the Odense study. Acta Psychiatr. Scand. 102 (2000) 331-335
17. Roth M., Tym E., Mountjoy C.Q., et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br. J. Psychiatry 149 (1986) 698-709
18. Diagnostic and Statistical Manual of Mental Disorders. 3rd edition (1987), American Psychiatric Association, Washington, DC
19. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34 (1984) 939-944
20. Engelhart M.J., Geerlings M.I., Meijer J., et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch. Neurol. 61 (2004) 668-672
21. Dik M.G., Jonker C., Hack C.E., Smit J.H., Comijs H.C., and Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology 64 (2005) 1371-1377
22. Gardai S.J., Xiao Y.Q., Dickinson M., et al. By binding SIRP-alpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 115 (2003) 13-23
23. Ohya M., Nishitani C., Sano H., et al. Human pulmonary surfactant protein D binds the extracellular domains of Toll-like receptors 2 and 4 through the carbohydrate recognition domain by a mechanism different from its binding to phosphatidylinositol and lipopolysaccharide. Biochemistry 45 (2006) 8657-8664
24. Hendrie H.C. Epidemiology of dementia and Alzheimer's disease. Am. J. Geriatr. Psychiatry 6 (1998) S3-S18
25. Sorensen G.L., Hjelmborg J.B., Kyvik K.O., et al. Genetic and environmental influences of surfactant protein D serum levels. Am. J. Physiol.: Lung Cell. Mol. Physiol. 290 (2006) L1010-L1017
26. Sunderland T., Hampel H., Takeda M., Putnam K.T., and Cohen R.M. Biomarkers in the diagnosis of Alzheimer's disease: are we ready?. J. Geriatr. Psychiatry Neurol. 19 (2006) 172-179
27. Seshadri S., Beiser A., Selhub J., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346 (2002) 476-483
28. McMahon J.A., Green T.J., Skeaff C.M., Knight R.G., Mann J.I., and Williams S.M. A controlled trial of homocysteine lowering and cognitive performance. N. Engl. J. Med. 354 (2006) 2764-2772
29. Lio D., Scola L., Romano G.C., Candore G., and Caruso C. Immunological and immunogenetic markers in sporadic Alzheimer's disease. Aging Clin. Exp. Res. 18 (2006) 163-166